Catalent, Inc. (NYSE:CTLT) Receives Consensus Recommendation of “Hold” from Analysts

Catalent, Inc. (NYSE:CTLT) has received a consensus rating of “Hold” from the seven ratings firms that are presently covering the company, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold recommendation and one has assigned a buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $58.08.

A number of research analysts have issued reports on CTLT shares. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a research note on Thursday, July 11th. Barclays lifted their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. StockNews.com initiated coverage on shares of Catalent in a research report on Wednesday. They set a “sell” rating on the stock. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd.

Catalent Stock Up 0.4 %

CTLT opened at $60.39 on Wednesday. The business’s 50-day simple moving average is $59.33 and its 200-day simple moving average is $57.15. The stock has a market capitalization of $10.93 billion, a P/E ratio of -9.90, a price-to-earnings-growth ratio of 1.88 and a beta of 1.15. Catalent has a one year low of $31.80 and a one year high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.77 and a current ratio of 2.52.

Insider Buying and Selling at Catalent

In other Catalent news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the sale, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total transaction of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The disclosure for this sale can be found here. Over the last three months, insiders have sold 13,409 shares of company stock valued at $782,923. Corporate insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Catalent

Large investors have recently bought and sold shares of the stock. Sanctuary Advisors LLC acquired a new position in shares of Catalent in the second quarter worth about $208,000. Truist Financial Corp raised its holdings in Catalent by 37.2% in the 2nd quarter. Truist Financial Corp now owns 28,029 shares of the company’s stock worth $1,576,000 after purchasing an additional 7,600 shares during the period. Millennium Management LLC boosted its position in Catalent by 129.2% during the second quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock worth $229,416,000 after purchasing an additional 2,299,784 shares in the last quarter. MBB Public Markets I LLC acquired a new stake in Catalent in the second quarter valued at approximately $788,000. Finally, APG Asset Management N.V. increased its position in shares of Catalent by 26.8% in the second quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock valued at $8,157,000 after buying an additional 32,900 shares in the last quarter.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.